IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis |
| |
| Authors: | Yuki Mitarai Kazuhisa Nakashima Shohei Fukunaga Noriyoshi Ishikawa Takafumi Ito Yukari Tsubata Takeshi Isobe |
| |
| Affiliation: | 1.Department of Respiratory Medicine, National Hospital Organization Hamada Medical Center, Japan; 2.Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, Japan; 3.Division of Nephrology, Shimane University Faculty of Medicine, Japan; 4.Department of Pathology, Shonan Fujisawa Tokushukai Hospital, Japan |
| |
| Abstract: | A 70-year-old man received pembrolizumab as a second-line treatment for squamous cell lung cancer of the lower right lobe. After three courses, proteinuria and hematuria were observed, which worsened after seven courses. He was diagnosed with a combination of IgA nephropathy and active interstitial nephritis. Steroid pulse therapy was started, and the dose of prednisolone was gradually reduced from 60 mg/day. Renal dysfunction as an immune-related adverse event of pembrolizumab monotherapy for non-small cell lung cancer has been reported previously. Therefore, establishing a system for the early detection and treatment that distinguishes immune-related glomerular diseases is essential. |
| |
| Keywords: | pembrolizumab immune-related adverse events (irAEs) IgA nephropathy |
|
|
